In Vitro Efficacy of Ceftazidime-Avibactam on Carbapenem-Resistant Pseudomonas aeruginosa Isolates
Anatolian Journal of Pharmaceutical Sciences · 2025
DOI: 10.71133/anatphar.1630540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anatolian Journal of Pharmaceutical Sciences, 2025. Verfasst von Ahmet Mansur und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Pseudomonas aeruginosa is the main Pseudomonas species causing hospital infections. Ceftazidime-avibactam (CZA) is a new beta-lactam/beta-lactamase inhibitor combination effective against carbapenem-resistant P. aeruginosa isolates. The aim of this study was to evaluate the in vitro activity of CZA against carbapenem-resistant P. aeruginosa isolates. In hospitalized patient culture samples, 190 isolates that were evaluated as significant growth and identified as P. aeruginosa with the Vitek 2 Compact automated system (BioMérieux, France) and determined as imipenem resistant (≥ 8 mg/L) and meropenem resistant (≥ 16 mg/L)with the same system were included in the study. 88% (167/190) of P. aeruginosa strains were isolated from patients in intensive care units and 78% (148/190) from respiratory tract samples. CZA activity was studied with disk diffusion test (10-4 µg disk) and zone diameters
Zitieren
APA
Mansur, A., & Gündüz, A. (2025). In Vitro Efficacy of Ceftazidime-Avibactam on Carbapenem-Resistant Pseudomonas aeruginosa Isolates. Anatolian Journal of Pharmaceutical Sciences. https://doi.org/10.71133/anatphar.1630540
Vancouver
Mansur A, Gündüz A. In Vitro Efficacy of Ceftazidime-Avibactam on Carbapenem-Resistant Pseudomonas aeruginosa Isolates. Anatolian Journal of Pharmaceutical Sciences. 2025. doi:10.71133/anatphar.1630540
BibTeX
@article{Mansur2025,
author = {Mansur, Ahmet and Gündüz, Ayten},
title = {In Vitro Efficacy of Ceftazidime-Avibactam on Carbapenem-Resistant Pseudomonas aeruginosa Isolates},
journal = {Anatolian Journal of Pharmaceutical Sciences},
year = {2025},
doi = {10.71133/anatphar.1630540}
}
EUVIMED